Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and Bortezomib Refractory Multiple Myeloma”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32
Large-scale testing (Phase 3)Study completedNCT03110562
What this trial is testing

Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 402
Testing effectiveness (Phase 2)Study completedNCT01212952
What this trial is testing

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Refractory Multiple Myeloma
Mayo Clinic 50
Large-scale testing (Phase 3)Study completedNCT00514371
What this trial is testing

Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 22
Early research (Phase 1)Study completedNCT00006098
What this trial is testing

PS-341 in Treating Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT03136653
What this trial is testing

Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Molecular Partners AG 33
Early research (Phase 1)Study completedNCT00858234
What this trial is testing

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC 9
Testing effectiveness (Phase 2)WithdrawnNCT01329289
What this trial is testing

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma
University of Pittsburgh
Early research (Phase 1)Study completedNCT01485835
What this trial is testing

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Emory University 8
Testing effectiveness (Phase 2)Study completedNCT00483262
What this trial is testing

Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dana-Farber Cancer Institute 63
Testing effectiveness (Phase 2)Looking for participantsNCT02343042
What this trial is testing

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Karyopharm Therapeutics Inc 300
Testing effectiveness (Phase 2)UnknownNCT00334932
What this trial is testing

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Herbert Irving Comprehensive Cancer Center 32
Early research (Phase 1)Ended earlyNCT04956302
What this trial is testing

Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Abdullah Khan 1
Testing effectiveness (Phase 2)WithdrawnNCT01492881
What this trial is testing

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
Large-scale testing (Phase 3)Study completedNCT00111748
What this trial is testing

UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

Who this might be right for
Multiple Myeloma
University of Arkansas 180
Not applicableStudy completedNCT00440635
What this trial is testing

Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen-Cilag International NV 641
Testing effectiveness (Phase 2)Study completedNCT01053949
What this trial is testing

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

Who this might be right for
Multiple Myeloma
University Hospital, Lille 84
Testing effectiveness (Phase 2)WithdrawnNCT03701321
What this trial is testing

Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT00352742
What this trial is testing

ATN-224 and Bortezomib in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Attenuon 46
Testing effectiveness (Phase 2)Study completedNCT00814541
What this trial is testing

PAD. ICORG 05-01, V11

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Cancer Trials Ireland 53
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation